cevazuril 50 mg/ml, oral suspension for piglets and calves
ceva santé animale - toltrazuril - oral suspension - 50 milligram(s)/millilitre - toltrazuril - cattle, pigs - coccidiostats
baycox bovis 50 mg/ml oral suspension
bayer limited - toltrazuril - oral suspension - 50 mg/ml - toltrazuril - bovine - coccidiostats
baycox sheep, 50 mg/ml oral suspension
bayer limited - toltrazuril - oral suspension - 50 mg/ml - toltrazuril - ovine - coccidiostats
toltarox 50 mg/ml oral suspension for cattle
krka, d.d., novo mesto - toltrazuril - oral suspension - 50 mg/ml - toltrazuril - bovine - coccidiostats
baycox bovis 50mg/ml oral suspension
bayer limited - toltrazuril - oral suspension - 50 milligram(s)/millilitre - toltrazuril - cattle - coccidiostats
baycox sheep, 50 mg/ml oral suspension.
bayer limited - toltrazuril - oral suspension - 50 milligram(s)/millilitre - toltrazuril - sheep - coccidiostats
baycox bovis 50mg/ml oral suspension
elanco gmbh - toltrazuril - oral suspension - 50 milligram(s)/millilitre - toltrazuril
baycox sheep, 50 mg/ml oral suspension.
elanco gmbh - toltrazuril - oral suspension - 50 milligram(s)/millilitre - toltrazuril
inqovi 35/100 decitabine 35 mg and cedazuridine 100 mg tablet blister pack
otsuka australia pharmaceutical pty ltd - decitabine, quantity: 35 mg; cedazuridine, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - inqovi 35/100 is indicated for the treatment of adult patients with myelodysplastic syndromes (mds) intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups, and patients with chronic myelomonocytic leukaemia (cmml).
inqovi 35/100 decitabine 35 mg and cedazuridine 100 mg tablet bottle
otsuka australia pharmaceutical pty ltd - decitabine, quantity: 35 mg; cedazuridine, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - inqovi 35/100 is indicated for the treatment of adult patients with myelodysplastic syndromes (mds) intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups, and patients with chronic myelomonocytic leukaemia (cmml).